Viral features of lamivudine resistant hepatitis B genotypes A and D.
about
Treatment strategies according to genotype for chronic hepatitis B in childrenDiagnosis of viral hepatitis.Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis BHepatitis B virus genotyping among chronic hepatitis B individuals with resistance to Lamivudine in shahrekord, iran.Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients.Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypesResponse to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype DResistance to lamivudine therapy: is there more than meets the eye?Molecular virology in chronic hepatitis B: genotypes.Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Doubly Spliced RNA of Hepatitis B Virus Suppresses Viral Transcription via TATA-Binding Protein and Induces Stress Granule Assembly.Therapeutic implications of hepatitis B virus genotypes.Antiviral therapies: focus on hepatitis B reverse transcriptaseFuture prospectives for the management of chronic hepatitis B.Molecular testing in the diagnosis and management of chronic hepatitis BRole of viral factors in the natural course and therapy of chronic hepatitis B.Hepatitis B virus genotypes: natural history and implications for treatment.Management of antiviral drug resistance in chronic hepatitis BPrevalence of HBV genotypes among Egyptian hepatitis patients.Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection.Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo.Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China.Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran.Hepatitis B virus genotypes in Europe.Genotyping of hepatitis B virus in a cohort of patients evaluated in a hospital of Porto Alegre, South of Brazil.Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection.Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance
P2860
Q28066476-D904B03C-3F15-461B-A7A3-C3117861476AQ33557877-7363D43C-E605-4863-ABE3-872FB0D37F87Q33918275-42FD818B-57B9-4C13-86F8-900F902550D1Q34068574-BD71066A-39C3-45CE-BCC2-EF951F4930A8Q34433062-9444D452-8CB5-4930-8432-634F5C93008CQ34700034-DC641378-7A66-4C52-9621-605909CF0447Q34719476-A595B76D-55FF-4520-B384-7C4523C33E7FQ35073136-5B4E0F94-E4B9-489F-A884-2DAD93FFD713Q35597612-42E4B04B-282C-46AF-A789-46E6C36E52A1Q35980473-C7108FB2-AF43-4813-878E-FAF45D52B1E9Q36027130-22911CE9-8E1F-484F-B4B8-3265CBBF6E25Q36177722-DE5EE3BC-4C4D-4556-B2DF-BB1628F9D75DQ36281882-3C0FE404-4821-4373-8CDB-D9567479F187Q36338675-1C899DC8-662B-447F-B154-D8460226D57AQ36467514-4D825AF2-AE58-4FF0-956E-26EF3316572BQ36841719-E21A7AFD-DC71-45F8-ABBC-A7401C601909Q36881140-18F96C42-A4B1-48EE-A894-70098E401AF3Q37280144-0D5AB577-6FB5-4ABD-94BA-83B75E555D6EQ37346012-9FF10EB6-035A-4BA9-B86D-AA8696B84AAFQ38247981-B2310CBA-0ACE-4B77-BE7F-F67D2B400F5FQ39131034-984C8F2C-C335-43D7-BDF4-A91B6A364651Q40202952-ED231041-3EF2-4F3F-AD84-18309AC93240Q41844014-1DF1857C-4B6D-4B67-9E51-7BCC740350B3Q43012086-B81C468C-2F5D-4829-B821-DCE96E9A0295Q43037749-5A81F3CA-2480-4694-B4C9-F2F2E235418AQ43243611-92BD2BAC-203F-4B0E-A115-FB9B94167E44Q45275480-E37CA485-1A35-4C7A-839C-9F811B3DF5AFQ45375563-DDB2589F-B090-406D-946E-2E7DB957F9ACQ45377033-2219BFB2-AC24-4237-81EC-57C3F17B1203Q45407035-5EEC8834-78C6-44F0-AD7D-52ECBA7376C3Q46604911-CF22AAB8-8E23-4F58-9F11-2AD368C462EFQ46604917-A528DA0D-3B71-4F5A-A4C1-AC9ABA0DEF2AQ47585685-641EAAD9-C5D8-4754-83D0-21631D4A1C87Q56895288-0AD326E2-623F-45DE-B6B4-D5B28A2A8836
P2860
Viral features of lamivudine resistant hepatitis B genotypes A and D.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@en
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@nl
type
label
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@en
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@nl
prefLabel
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@en
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@nl
P2093
P2860
P356
P1433
P1476
Viral features of lamivudine resistant hepatitis B genotypes A and D.
@en
P2093
Bernhard Zöllner
Elisabeth Puchhammer-Stöckl
Heinz-Hubert Feucht
Josef Kletzmayr
Jörg Petersen
Lutz Fischer
Martina Sterneck
Matthias Schröter
Rainer Laufs
P2860
P356
10.1002/HEP.20016
P407
P577
2004-01-01T00:00:00Z